Immediate Impact

1 by Nobel laureates 2 from Science/Nature 55 standout
Sub-graph 1 of 22

Citing Papers

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
2023 Standout
Prostate cancer
2021 Standout
2 intermediate papers

Works of Mohamed Darif being referenced

Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC)
2019
Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial.
2018

Author Peers

Author Last Decade Papers Cites
Mohamed Darif 475 319 288 28 794
M. Hoffmann 504 125 206 19 653
Marilena Bellò 330 193 302 29 870
John H. Barton 344 92 520 32 875
Kazushige Tsutsui 265 88 186 31 843
Eve Gallop‐Evans 579 114 358 27 845
Niels Murawski 697 123 474 38 936
J M Connors 553 55 390 16 935
Patrizia Albertini 566 45 257 17 699
Viola Poeschel 680 118 444 38 833
Elaine K. Wong 264 63 561 19 910

All Works

Loading papers...

Rankless by CCL
2026